Global expansion Curium aims to expand into key markets in Japan and China as part of its 2030 oncology-focused nuclear medicine strategy, presenting opportunities to partner on localized supply, regulatory navigation, and joint market entry initiatives.

Prostate cancer focus Significant investments in Lu-177 based PSMA therapies and upcoming U.S. launches create avenues to engage urology and oncology networks, secure distribution partnerships, and support product reimbursement discussions.

Neuroendocrine niche Current focus on neuroendocrine tumors with Lutetium DOTATATE products offers cross-sell potential to centers treating NETs, enabling bundled radiopharmaceuticals and integrated imaging-therapy solutions.

Recent litigation victory Successful resolution of patent disputes around Lutetium Lu-177 dotatate strengthens sales credibility and can be leveraged to accelerate market access, customer reassurance, and channel expansion.

Strategic facility investments EUR 32 million investment in Saclay to establish European production for Lu-PSMA-I&T creates capacity and supply security; this supports new deal structures with European hospitals and cancer centers seeking reliable radiopharmaceutical supply.